Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth CCI-779 Survival Benefit Over Interferon In Kidney Cancer May Warrant First-Line Use

This article was originally published in The Pink Sheet Daily

Executive Summary

CCI-779 (temsirolimus) monotherapy is associated with a 49% improvement in median overall survival compared to interferon in advanced renal cell carcinoma patients.

You may also be interested in...



Wyeth Submits NDA For Temsirolimus In Kidney Cancer

Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.

Wyeth Submits NDA For Temsirolimus In Kidney Cancer

Torisel would be the only renal cell carcinoma drug on the market to offer a significant survival benefit, Wyeth says.

Wyeth Will Develop Rapamycin Analogs Under Alliance With Biotica

Deal builds on Wyeth's Rapamune expertise.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel